Key result
Ranolazine improves mouse HCM cardiomyocyte workload tolerance but fails to reverse in vivo hypertrophy or dysfunction.
Why the study?
Does ranolazine improve cardiac hypertrophy and dysfunction in a mouse model of hypertrophic cardiomyopathy?
Does ranolazine improve cardiac hypertrophy and dysfunction in a mouse model of hypertrophic cardiomyopathy?
Ranolazine improves tolerance to high workload in isolated HCM cardiomyocytes via β-adrenergic antagonism but lacks long-term therapeutic efficacy in vivo.
No takes yet. Share an insight, caveat, or question.
No immediate change to HCM practice; leaves open whether cellular workload benefits translate in patients.
Flenner et al. (2015) studied Hypertrophic cardiomyopathy. Ranolazine vs. Wild-type (WT) cardiomyocytes / absence of ranolazine was evaluated on Cardiac hypertrophy or dysfunction in KI mice. Ranolazine improved tolerance to high workload in mouse HCM cardiomyocytes by antagonizing β-adrenergic stimulation, but 6-month treatment did not reverse cardiac hypertrophy or dysfunction in vivo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: